BioSpace News Archive

The Automated Insulin Delivery (AID) solutions developed by Diabeloop embed therapeutic artificial intelligence to automate and personalize Type 1 diabetes management.

Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced that it has expanded its generic portfolio with the recent launch of three new products: Fluvoxamine Maleate Tablets, Haloperidol Tablets, USP, and Clonidine Hydrochloride Extended-Release Tablets

Lark Health, the leading chronic disease prevention and management platform, announced the continuation of a contract with HealthPartners after a pilot period.

The leader in women’s and family health expands into payments with the launch of Maven Wallet

Meridian Bioscience, Inc. (NASDAQ: VIVO) and Exalenz Bioscience Ltd. (TASE: EXEN) announced today that the two companies have entered into a definitive agreement for Meridian to acquire Exalenz for ₪6.10 per share in cash with an implied transaction value of approximately $49 million.

AUSTIN, Texas, Feb. 19, 2020 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) (“XBiotech”) today announced the final results of its “modified Dutch auction” tender offer, which expired at 5:00 p.m., New York City time, on February 12, 2020. Based on the final count by American Stock Transfer & Trust Co., LLC, the depositary for the tender offer, a total of 40,007,286 common shares, no par value, were properly tendered and not properly withdrawn at or below the maximum purchase price of $

Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that it will report fourth quarter and full year 2019 financial results on Thursday, February 27, 2020 prior to the open of the market.

Thesecondopinion, a nonprofit offering free multidisciplinary, comprehensive second opinions to adults diagnosed with new or recurrent cancers, announced today it is hosting Dr. Robert M. Sapolsky—one of the world’s leading neuroscientists and acclaimed best-selling author, stress expert and biologist—at its 6th Annual Benefit event.

RIBOMIC, Inc., a clinical stage pharmaceutical company specializing in aptamer therapeutics and traded on the Mothers Market of the Tokyo Stock Exchange (Code Number: 4591), today announced that first patient has received injection in the phase 2 trial of RBM-007 for the treatment of exudative age-related macular degeneration (AMD) in the United States.

LivaNova PLC commends the recent international consensus statement published in the Journal of Affective Disorders for recommendations to identify, assess and manage depression for patients unable to achieve or sustain symptom remission despite serial treatment trials.1 While the diagnosis for these patients is often “Treatment-Resistant Depression”, the authors conclude that “Difficult-to-treat Depression” has semantic and conceptual advantages.